Page 36 - GPD-3-1
P. 36

Gene & Protein in Disease                                         Natural carotenoids prevent prostate cancer



               evidence for the formation of a complex between 1-cysteine   20.  Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR,
               peroxiredoxin and glutathione S-transferase π with activity   Cooney KA. Risk of prostate cancer associated with
               changes in both enzymes. Biochemistry. 2005;45(2):360-372.  familial and hereditary cancer syndromes.  J  Clin Oncol.
                                                                  2020;38(16):1807-1813.
               doi: 10.1021/bi0520737
                                                                  doi: 10.1200/jco.19.02808
            9.   Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Epigenetics
               in prostate cancer: Clinical implications. Transl Androl Urol.   21.  Gandaglia G, Leni R, Bray F,  et al. Epidemiology
               2021;10(7):3104-3116.                              and prevention of prostate cancer.  Eur Urol Oncol.
                                                                  2021;4(6):877-892.
               doi: 10.21037/tau-20-1339
                                                                  doi: 10.1016/j.euo.2021.09.006
            10.  Adjakly M, Ngollo M, Dagdemir A, et al. Prostate cancer: The
               main risk and protective factors - epigenetic modifications.   22.  Wu I, Modlin CS. Disparities in prostate cancer in African
               Ann Endocrinol (Paris). 2015;76(1):25-41.          American men: What primary care physicians can do. Cleve
                                                                  Clin J Med. 2012;79(5):313-320.
               doi: 10.1016/j.ando.2014.09.001
                                                                  doi: 10.3949/ccjm.79a.11001
            11.  Grozescu T, Popa F. Prostate cancer between prognosis and
               adequate/proper therapy. J Med Life. 2017;10:5-12.  23.  Powell IJ, Bollig-Fischer A. Minireview: The molecular and
                                                                  genomic basis for prostate cancer health disparities.  Mol
            12.  Watts EL, Perez‐Cornago A, Fensom GK, et al. Circulating
               free testosterone and risk of aggressive prostate cancer:   Endocrinol. 2013;27(6):879-891.
               Prospective and mendelian randomisation analyses in      doi: 10.1210/me.2013-1039
               international consortia. Int J Cancer. 2022;51(7):1033-1046.
                                                               24.  Pourmand G, Salem S, Mehrsai A, et al. The risk factors of
               doi: 10.1002/ijc.34116                             prostate cancer: A multicentric case-control study in Iran.
                                                                  Asian Pac J Cancer Prev. 2007;8(3):422-428.
            13.  Li J, Coates RJ, Gwinn M, Khoury MJ. Steroid 5- -reductase
               type 2 (SRD5a2) gene polymorphisms and risk of prostate   25.  Benke IN, Leitzmann MF, Behrens G, Schmid D. Physical
               cancer: A HuGE review. Am J Epidemiol. 2009;171(1):1-13.  activity in relation to risk of prostate cancer: A systematic
                                                                  review and meta-analysis. Ann Oncol. 2018;29(5):1154-1179.
               doi: 10.1093/aje/kwp318
                                                                  doi: 10.1093/annonc/mdy073
            14.  Liu WJ, Zhao G, Zhang CY, et al. Comparison of the roles
               of estrogens and androgens in breast cancer and prostate   26.  Krstev S, Knutsson A. Occupational risk factors for prostate
               cancer. J Cell Biochem. 2020;121(4):2756-2769.     cancer: A meta-analysis. J Cancer Prev. 2019;24(2):91-111.
               doi: 10.1002/jcb.29515                             doi: 10.15430/jcp.2019.24.2.91
            15.  Hu X, Wang YH, Yang ZQ, et al. Association of 5-alpha-  27.  Oczkowski M, Dziendzikowska K, Pasternak-Winiarska A,
               reductase inhibitor and prostate cancer incidence   Włodarek D, Gromadzka-Ostrowska J. Dietary factors and
               and  mortality: A  meta-analysis.  Transl  Androl Urol.   prostate cancer development, progression, and reduction.
               2020;9(6):2519-2532.                               Nutrients. 2021;13(2):496.
               doi: 10.21037/tau-20-843                           doi: 10.3390/nu13020496
            16.  Perdana NR, Mochtar CA, Umbas R, Hamid ARA. The risk   28.  Kimura T, Egawa S. Epidemiology of prostate cancer in
               factors of prostate cancer and its prevention: A  literature   Asian countries. Int J Urol. 2018;25(6):524-531.
               review. Acta Med Indones. 2016;48(3):228-238.
                                                                  doi: 10.1111/iju.13593
            17.  Bergengren O, Pekala KR, Matsoukas K, et al. Update on   29.  Masuda H, Kagawa M, Kawakami S, et al. Body mass index
               prostate cancer epidemiology and risk factors-a systematic   influences prostate cancer risk at biopsy in Japanese men. Int
               review. Eur Urol. 2023;84(2):191-206.
                                                                  J Urol. 2013;20(7):701-707.
               doi: 10.1016/j.eururo.2023.04.021
                                                                  doi: 10.1111/iju.12023
            18.  Johns LE, Houlston RS. A  systematic review and   30.  Cerhan JR, Torner JC, Lynch CF,  et al. Association of
               meta-analysis of familial prostate cancer risk.  BJU Int.   smoking, body mass, and physical activity with risk of
               2003;91(9):789-794.
                                                                  prostate cancer in the Iowa 65+ rural health study (United
               doi: 10.1046/j.1464-410x.2003.04232.x              States). Cancer Causes Control. 1997;8(2):229-238.
            19.  Hemminki K, Czene K. Age specific and attributable risks      doi: 10.1023/a:1018428531619
               of familial  prostate  carcinoma from the  family-cancer   31.  Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N.
               database. Cancer. 2002;95(6):1346-1353.
                                                                  Obesity, inflammation, and prostate cancer.  J  Clin  Med.
               doi: 10.1002/cncr.10819                            2019;8(2):201.



            Volume 3 Issue 1 (2024)                         12                       https://doi.org/10.36922/gpd.2827
   31   32   33   34   35   36   37   38   39   40   41